

Disorders therapy markets

US lives, and partners


Reward system
e.g. Ventral Striatum
RDoC: Positive Valence



Cognitive system
e.g. Right IFG
RDoC: Cognitive







Emotion regulation system
e.g. amygdala
RDoC: Negative Valence



SUD – Substance Use Disorder
MDD – Major Depressive Disorder
BPD – Borderline Personality Disorder
GAD – General Anxiety Disorder
PTSD – Post Traumatic Stress Disorder
ADHD – Attention-deficit/hyperactivity disorder


GrayMatters Health Proprietary and Confidential

Applications roadmap

	Discovery	Feasibility	Pivotal	Commercial	
PTSD ¹					 Large US HMO1
MDD anhedonia					
ADHD					
BPD					
SUD					Large US HMO2
Prediction and personalization					


1 - completed a 79pt study in 5 sites in the USA and Israel; initiated a 5 site study in Germany; Working with a large US HMO on a pre commercial study; more
2 - feasibility on going, preparing for pivotal

Timeline to market: PTSD and beyond




Pipeline

Additional disorders therapy



- Emotion regulation system
- Reward system
- Cognitive system


Service provider & clinic to home setting



Clinic




Home



Evaluating several OEM options

Data driven services



Clinic

De-identified therapy data



New treatment protocols


Analytics engine

- Personalized protocols
- Quantified psychiatric diagnostics

The device-data iceberg value

Today: Improved healthcare outcomes, high safety profile, existing CPT codes, clinic workflow ready

Future: Therapy personalization and prediction, patient management, pharmacotherapy dose optimization



1 – Devices – Prism installations including Prism software and hardware, initially at the clinics, and at home in the future

2 – Data points – EFP measurements calculated as patients perform the 30 minute Prism therapy sessions (1200 data points per session), plus periodic psychiatric questionnaires

3 – all data to be tokenized

Recognition and network

■ Recognitions and awards

- **May 2021** - selected by [NYC HITLAB Breakthrough Alliance](#) as the company they will work with to infuse to the NYC Healthcare system, out of more than 100 companies
- **May 2021** - Selected to join **German 5-HT Digital Hub** as a 1st step of being introduced to the German ecosystem
- **May 2021** – approved for a 2nd IIA non-dilutive grant in total \$1.25M
- **Jun 2021** - **won 1st place** in the Medtech1 track at the USA Government Department of Commerce **SelectUSA** conference
- **Jun 2021** - [featured by Nature Magazine](#) as one of the top 8 companies in the 2021 #Spinoff Prize - innovative spin-offs based on academic research
- **Jun 2021** – Receptient of a \$1M non-dilutive [BIRD grant](#) - for developing MDD solution together with McLean Hospital (Harvard)
- **Dec 2021** – [Red Herring](#) Europe Top 100 Winner list
- **Dec 2021** – awarded the [EIC Accelerator €2.5M grant](#)
- **Dec 2021** – completed a [\\$10M Series A round led by Otsuka Medical Device Japan](#) + commercialization agreement
- **Feb 2023** – [EIC Fund advised by EIB investment in GMH](#)
- **Mar 2023** – [FDA clearance for Prism for PTSD](#)

■ Clinical partners and collaborations

